Pfizer Sales of and distributions from equity method investments decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $6.31B to $0.00. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher proceeds suggest successful asset rotation or strategic exit from partnerships, providing liquidity for other investments.
Cash inflows resulting from the divestiture or liquidation of interests in entities accounted for under the equity metho...
Standard for midstream companies that frequently utilize joint ventures for large-scale infrastructure projects.
other_proceeds_from_sale_of_equity_method_investments| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $3.49B | $3.55B | $6.31B | $0.00 |
| QoQ Change | — | — | — | — | — | — | — | — | — | +1.7% | +77.8% | -100.0% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | +80.8% | -100.0% |